VP, Global Communications & Public Affairs ● Google ● San Francisco
He started his career looking at sheep diseases in Edinburgh. Now he manages the public voice of one of the most watched companies on the planet. The distance between those two facts is the story.
Shaping the public narrative around Google's role in AI, antitrust battles, cloud computing, and the future of search - at the moment when every word from Mountain View carries global weight.
In 1998, Ross Wilkie graduated from the University of Edinburgh with a BSc (Honours) in Biological Sciences and took a job that had nothing to do with press releases, corporate strategy, or boardrooms. He became an immunology research scientist at the Moredun Research Institute - a Scottish agricultural research body where the subject of study was animal health and disease.
He spent a year in that lab. Then he walked out and never looked back - into public relations, corporate communications, and eventually the upper echelons of global business leadership. The pivot wasn't random. It was a deliberate translation. Someone who can explain immunology to farmers can explain anything to anyone. That capacity to bridge complexity and clarity became his career's through-line.
From Moredun, he moved into PR agency life - first at Chime Group, then as Group Account Director for Healthcare at Ketchum, the global communications firm. He was already building a specialization: scientific and medical communications, at a time when the pharmaceutical industry was beginning to understand that how you say something is just as important as what you say.
"From Moredun Research Institute to Mountain View - the distance between those two facts is the story."
Ross Wilkie's career arc, in one sentenceBetween 2007 and 2009, he added a different kind of credibility: strategy. At Accenture, as a Senior Manager in Health and Life Sciences, he learned how corporations actually think - not just what they say publicly, but how decisions get made, where the gaps between intention and communication live, and what it costs when those gaps become visible.
That combination - scientific literacy, communications craft, strategic consulting rigor - made him unusual. In a world full of communications executives who came up through media relations or journalism, Wilkie arrived from the other direction entirely.
Most communications executives come up through journalism or media relations. Wilkie came from a lab bench. That scientific literacy - knowing how to evaluate evidence, communicate uncertainty, and translate complexity - runs through everything he does.
GlaxoSmithKline is one of the most complex communications environments on earth. You're managing government relations across dozens of markets. You're handling drug approvals, pipeline announcements, patent disputes, pricing controversies, and the occasional crisis that spills across three continents before Monday morning. Ross Wilkie spent roughly twenty years learning that machine from the inside.
He didn't enter as a senior figure. He came in as Head of Communications for Pharmaceuticals, R&D and Pipeline - a role that put him at the intersection of science and public narrative. Drug pipelines are notoriously difficult to communicate: failure rates are high, expectations run wild, and the gap between "promising trial results" and "medicine on shelves" can be a decade wide. Wilkie learned to navigate that gap.
He rose steadily. VP for Communications covering Europe, Emerging Markets, and Asia-Pacific was a span that required managing teams across time zones, cultures, and regulatory environments. The messages that work in London don't always work in Seoul or Sao Paulo. Building that kind of global communications fluency takes years.
By the time he reached Senior Vice President level - first for Communications & Government Affairs in Pharma, then for Science & Innovation broadly - he had essentially touched every dimension of a major multinational's communications challenge: media, government, internal, crisis, reputation. Eventually, the CCO seat.
Pharma, R&D & Pipeline - where science meets public narrative. Managing the gap between laboratory promise and market reality.
Europe, Emerging Markets, Asia-Pacific & Japan - multi-continent scope, multi-cultural messaging, one coherent story.
Pharma division - adding government relations to the communications portfolio. Policy, regulation, and reputation as one function.
The full scientific story of one of the world's largest drug companies. Translating pipelines, trials, and breakthroughs for global audiences.
The top of the GSK communications structure. Global accountability for one of the most scrutinized sectors in business.
Danaher Corporation is not a household name, but it should be. A $40 billion industrial science conglomerate that owns dozens of companies across water quality, life sciences, and diagnostics, Danaher operates on a scale that most people never see. Ross Wilkie arrived in October 2022 as its Chief Communications Officer.
Eighteen months. That's not long to rewrite a company's communications from the ground up, but that's what the record shows. During his tenure, Wilkie modernized Danaher's corporate communications structure, brought in key talent, refreshed the corporate brand and company narrative, rebuilt the digital infrastructure, and initiated a three-year strategic program to reposition the company in the public consciousness.
He also managed communications through what the company described as "some big issues and multi-billion dollar M&A" - the kind of work where the wrong word at the wrong moment can move markets or derail deals worth billions.
When he left for Google in early 2024, he had compressed a substantial transformation into a short window. That kind of concentrated impact - moving fast, building durable structures, then leaving cleanly - is a specific kind of leadership skill. Not everyone can do it.
New structure, new talent, new ways of working. Bringing Danaher's corporate communications into alignment with the company's actual scale and ambition.
Rebuilt Danaher's corporate brand and digital infrastructure from the ground up, giving one of America's most successful conglomerates a public identity that matched its private excellence.
Managing the communications dimension of major transactions requires precision under pressure. Wilkie handled it during Danaher's active deal period.
February 2024. Ross Wilkie joins Google as VP, Global Communications & Public Affairs - and steps into one of the most demanding communications roles in the world. Google is simultaneously defending itself in a landmark antitrust lawsuit, launching an AI platform against fierce competition from OpenAI and Microsoft, managing global regulatory pressure in Europe and beyond, and trying to communicate clearly about products that touch three billion people's daily lives.
The product portfolio alone is staggering. Search. YouTube. Maps. Gmail. Chrome. Android. Google Photos. Google Play. Gemini. Google Cloud. Pixel. Workspace. Each one is its own communications challenge. Each one has its own audiences, its own critics, its own political and regulatory context.
Wilkie's background gives him a specific kind of readiness for this. Big Pharma communications, at the senior level, involves explaining products that people trust with their lives, navigating regulatory environments that can overturn years of work overnight, and managing the gap between what a company knows and what it can legally or strategically say publicly. That is not entirely unlike the position Google finds itself in on AI safety, content moderation, or data privacy.
"The discipline of Big Pharma communications - explaining complex products to anxious audiences while navigating regulatory scrutiny - maps directly onto the challenge of communicating about AI in 2024."
An observation on Wilkie's career transitionBased in San Francisco, Wilkie is working in the city where the cultural and political scrutiny of Silicon Valley is most concentrated - while Google's engineering heartbeat remains in Mountain View, 35 miles south. That geographic positioning is itself a kind of bridge.
The Google he joined is not the Google of the early 2010s - confident, expanding, largely celebrated. It's a Google under real pressure: antitrust, AI ethics, content decisions, market dominance questions. The communications work now is harder, more high-stakes, and more geopolitically complex than at any point in the company's history. Wilkie arrived just in time.
Almost no communications executive at this level has a hard science degree and lab experience. That background - understanding how evidence works, how uncertainty should be communicated, how complexity can be translated without being falsified - is rare and valuable.
Pharma. Medical devices. Industrial science. Big tech. Each requires a completely different communications vocabulary, regulatory context, and audience relationship. Wilkie has navigated all four. That kind of range is genuinely unusual at CCO level.
He learned the craft in agencies (Chime, Ketchum) before taking it in-house. That trajectory matters: agency work teaches you to communicate about things you don't control, which is excellent preparation for every communications challenge that follows.
The Accenture chapter is often overlooked but it's significant. Strategy consulting teaches you how organizations actually think - which is often quite different from how they say they think. That inside knowledge shapes better communications.
Managing communications for GSK's European, Emerging Markets, and Asia-Pacific regions means building real fluency in how messages travel differently across cultures. That's not a skill you can fake, and it's directly relevant to Google's global regulatory environment.
Joining Google in February 2024 - mid-antitrust trial, mid-AI arms race, mid-regulatory reckoning - is not the safe choice. It's the interesting one. Someone who spent 20 years communicating about drug safety and government affairs knows exactly what the next few years at Google will look like.
The University of Edinburgh, founded in 1583, is one of the world's great research universities and the sixth-oldest in the English-speaking world. Its School of Biological Sciences is internationally recognized. Wilkie graduated with honours in 1998 - the same year Google was founded.
That's not just a coincidental date. It's a reminder that the world Ross Wilkie studied in, and the world he now inhabits professionally, emerged from the same late-1990s moment. He graduated into a world before the smartphone, before social media, before the algorithmic feed - and has spent his career adapting his communications craft to each successive wave of change.
The scientific training from Edinburgh runs through his approach to communications in ways that are hard to articulate but easy to spot: precision over hyperbole, evidence over assertion, awareness of what can and can't be said given what is actually known. In an industry prone to overstatement, that's a competitive advantage.
🏭 Founded 1583 - one of the world's oldest universities
🏭 Top 20 globally for life sciences
🏭 Edinburgh's School of Biological Sciences is internationally recognized for research
🏭 The scientific training that shaped a 28-year communications career
Not "worked near scientists" or "managed science teams." He was in a laboratory studying immunology. That makes his ability to navigate scientific communications at Google, GSK, and Danaher qualitatively different from most peers.
His GSK VP role covered Europe, Emerging Markets, Asia-Pacific, and Japan - which is effectively a communications mission across five continents simultaneously. That kind of global span doesn't come from most careers.
Eighteen months at Danaher. That's not a short stint - it's a deliberate, concentrated intervention. He built structures designed to outlast his tenure. That's a specific leadership philosophy: leave the organization better than you found it, quickly.
Joining Google's communications team in 2024 - mid-antitrust, mid-AI revolution - is not the conservative career choice. It's the choice of someone who finds complicated problems interesting.
From Edinburgh's Old Town, where the University of Edinburgh has stood since 1583, to San Francisco's tech-drenched neighborhoods - Wilkie's geography tells the story of global ambition from an old-world scientific foundation.
Moredun Research Institute, where Wilkie spent his first professional year, specializes in animal health and disease. The skills required to communicate complex veterinary science to farming communities aren't entirely unlike explaining AI to Congress.